Abstract | BACKGROUND: OBJECTIVE: To evaluate the efficacy of a combination of systemic clindamycin (300 mg twice daily) and rifampicin (600 mg daily) in the treatment of patients with severe HS. METHODS: Patients (n = 116) who received this combination were studied retrospectively. The main outcome measure was the severity of the disease, assessed by the Sartorius score, before and after 10 weeks of treatment. RESULTS: The Sartorius score dramatically improved at the end of treatment (median = 29, interquartile range = 14.5, vs. median = 14.5, interquartile range = 11; p < 0.001), as did other parameters of severity as well as the quality of life score. Eight patients (6.9%) stopped the treatment because of side effects. CONCLUSION:
|
Authors | G Gener, F Canoui-Poitrine, J E Revuz, O Faye, F Poli, G Gabison, F Pouget, C Viallette, P Wolkenstein, S Bastuji-Garin |
Journal | Dermatology (Basel, Switzerland)
(Dermatology)
Vol. 219
Issue 2
Pg. 148-54
( 2009)
ISSN: 1421-9832 [Electronic] Switzerland |
PMID | 19590173
(Publication Type: Journal Article)
|
Copyright | Copyright 2009 S. Karger AG, Basel. |
Chemical References |
|
Topics |
- Administration, Oral
- Clindamycin
(administration & dosage)
- Cohort Studies
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Hidradenitis Suppurativa
(diagnosis, drug therapy)
- Humans
- Male
- Patient Satisfaction
(statistics & numerical data)
- Quality of Life
- Retrospective Studies
- Rifampin
(administration & dosage)
- Severity of Illness Index
- Treatment Outcome
|